Cargando…

Supplementary Prognostic Variables for Pleural Mesothelioma: A Report from the IASLC Staging Committee

INTRODUCTION: The staging system for malignant pleural mesothelioma is controversial. To revise this system, the International Association for the Study of Lung Cancer Staging Committee developed an international database. This report analyzes prognostic variables in a surgical population, which are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pass, Harvey I., Giroux, Dorothy, Kennedy, Catherine, Ruffini, Enrico, Cangir, Ayten K., Rice, David, Asamura, Hisao, Waller, David, Edwards, John, Weder, Walter, Hoffmann, Hans, van Meerbeeck, Jan P., Rusch, Valerie W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132031/ https://www.ncbi.nlm.nih.gov/pubmed/24807157 http://dx.doi.org/10.1097/JTO.0000000000000181

Ejemplares similares

From the IASLC Tobacco Control Committee
Publicado: (2020)

From the IASLC Tobacco Control Committee
Publicado: (2020)

From the IASLC Tobacco Control Committee
Publicado: (2020)

From the IASLC Tobacco Control Committee
Publicado: (2020)

Comment on “EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach”
por: Vigneswaran, Wickii T., et al.
Publicado: (2020)

The prognostic value of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography parameters in patients with malignant pleural mesothelioma
por: Yenigün, Bülent Mustafa, et al.
Publicado: (2021)

Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis
por: Schillebeeckx, Eline, et al.
Publicado: (2021)

Development of a Biosensor for Detection of Pleural Mesothelioma Cancer Biomarker Using Surface Imprinting
por: Mathur, Aabhas, et al.
Publicado: (2013)

Onconase Mediated NFKβ Down-Regulation in Malignant Pleural Mesothelioma
por: Goparaju, Chandra M., et al.
Publicado: (2011)

Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma
por: Moro, Jacopo, et al.
Publicado: (2022)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
por: Treasure, Tom, et al.
Publicado: (2011)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches—a narrative review
por: Zolondick, Alicia A., et al.
Publicado: (2021)

Gli as a Novel Therapeutic Target in Malignant Pleural Mesothelioma
por: Li, Hui, et al.
Publicado: (2013)

Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2017)

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
por: Sato, Hiroki, et al.
Publicado: (2018)

Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma
por: Lauk, Olivia, et al.
Publicado: (2021)

IASLC Textbook of Prevention and Early Detection of Lung Cancer
por: Spiro, S G
Publicado: (2006)

External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
por: Janssens, Eline, et al.
Publicado: (2022)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Disulfiram Suppresses Growth of the Malignant Pleural Mesothelioma Cells in Part by Inducing Apoptosis
por: Cheriyan, Vino T., et al.
Publicado: (2014)

New International Association for the Study of Lung Cancer (IASLC) Pathology Committee Grading System for the Prognostic Outcome of Advanced Lung Adenocarcinoma
por: Weng, Ching-Fu, et al.
Publicado: (2020)

Controversies in the role of radiotherapy in pleural mesothelioma
por: Hanna, Gerard G., et al.
Publicado: (2021)

Proposal for a new local recurrence score in patients with recurrent malignant pleural mesothelioma
por: Lauk, Olivia, et al.
Publicado: (2022)

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

CD74: a new prognostic factor for patients with malignant pleural mesothelioma
por: Otterstrom, C, et al.
Publicado: (2014)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis
por: Thies, Svenja, et al.
Publicado: (2015)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Heparanase inhibitors restrain mesothelioma
por: Lapidot, Moshe, et al.
Publicado: (2018)

The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
por: Banerji, Shantanu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ufangm8me1krrq93j5sv4ipq8